ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN : U85191DL2011PLC216530

14th August, 2019

The Secretary National Stock Exchange of India Ltd Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400051 Trading Symbol: AGLSL	The Secretary BSE Ltd PhirozeJeejeebhoy Towers, Dalal Street, Mumbai – 400001 Scrip Code:540616

Sub: Outcome of the Board Meeting held on 14th August, 2019

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Board of Directors of the Company in their meeting held on 14.08.2019 have inter alia, considered and approved the following:

Approved the Unaudited Financial results (Standalone and Consolidated) for the quarter ended 30th June, 2019 as recommended by the Audit Committee.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of duly signed un-audited financial results (Standalone and Consolidated), along with the Limited Review report by statutory auditor of the Company thereon, are attached herewith.

The Board Meeting commenced at 7:30 AM [illegible]

Please take the above information on your records.

ANAND DUA & ASSOCIATES
Chartered Accountants

Flat No 11, Pocket-7, Sector-12,
Dwarka, New Delhi-110 078
Email: anand.dua@gmail.com
Ph: 47021279

Review report

To
The Board of Directors
Artemis Global Life Sciences Limited

We have reviewed the accompanying statement of unaudited financial results of Artemis Global Life Sciences Limited ('the Company') for the quarter ended 30th June, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Anand Dua & Associates
Chartered Accountants
FRN: 04263N

Place: New Delhi

ANAND DUA & ASSOCIATES
Chartered Accountants

Flat No 11, Pocket-7, Sector-12,
Dwarka, New Delhi-110 078
Email: anand.dua@gmail.com
Ph: 47021279

[redacted]

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the *SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as* amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Attention is drawn to Note No. 4 of the unaudited consolidated financial results informing that Composite Scheme of Amalgamation for amalgamating Aretmis Health Science Limited, Artemis Medicare Services Limited and Athena Eduspark Limited with the Parent company was filed with the National Company Law Tribunal New Delhi Bench -III, at New Delhi (NCLT). NCLT reserved the order for pronouncement, subject to clarification on August 1, 2019.

   Our conclusion is not modified in respect of this matter.

7. We did not review the interim financial results of four subsidiaries (including step down subsidiaries) included in the Group, whose results reflect total revenues of Rs. 13,570.76 lakhs, total net profit after tax of Rs. 438.30 lakhs and total comprehensive income of Rs. 437.18 lakhs for the quarter ended as considered in the consolidated unaudited financial results of the entities included in the Group. The interim financial results of these subsidiaries have been reviewed by the other auditors whose reports

[redacted]

have been furnished to us, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of such auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

For Anand Dua & Associates
Chartered Accountants
FRN: 04263N



(Anand Dua)
Partner
M.No. 083503
UDIN - 19083503AAAAZ09488

Place: New Delhi
Date: 14/08/2019

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN : U85191DL2011PLC216530

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019

(Rs. in Lakh)

S No.	Particulars	Quarter ended			Year ended
		30-Jun-19 (Unaudited)	31-Mar-19 (Audited) (Refer note 4)	30-Jun-18 (Unaudited)	31-Mar-19 (Audited)
1	Revenue from operations*	10.20	10.20	10.20	40.80
2	Other income	-	-	-	-
3	**Total Income**	**10.20**	**10.20**	**10.20**	**40.80**
	Expenses				
	Employee Benefits expenses	9.43	6.32	6.15	24.84
	Finance costs	-	-	-	-
	Depreciation and amortization expense	3.76	3.73	3.76	15.10
	Other expenses	6.91	7.09	8.23	40.20
4	**Total expenses**	**20.10**	**17.13**	**18.14**	**80.14**
5	**Profit/(Loss) before Tax and exceptional items**	**(9.90)**	**(6.93)**	**(7.94)**	**(39.34)**
6	Exceptional Items	-	-	-	-
7	**Profit before tax**	**(9.90)**	**(6.93)**	**(7.94)**	**(39.34)**
8	**Tax Expense**				
	Current Tax				
	Deferred tax	1.80	(21.46)	(2.07)	(27.65)
	Total tax expense	**1.80**	**(21.46)**	**(2.07)**	**(27.65)**
9	**Profit for the period**	**(11.70)**	**14.53**	**(5.87)**	**(11.69)**
10	**Other comprehensive income**				
I	Items that will not be reclassified to profit or loss				
a	*gains / (losses) on defined benefit plans*	-	-	-	-
b	Deferred tax adjustment on revaluation	-	-	-	-
c	Income tax relating to items that will not be reclassified to profit & loss	-	-	-	-
II	Net other comprehensive income not to be reclassified to profit or loss in subsequent periods:	-	-	-	-
	Other comprehensive income for the period, net of income tax	-	-	-	-
11	**Total comprehensive income/(loss) ('OCI')**	**(11.70)**	**14.53**	**(5.87)**	**(11.69)**
12	**Paid up equity share capital (Face value Rs. 2/- each)**	**1,323.77**	**1,323.77**	**1,323.77**	**1,323.77**
13	**Other equity excluding revaluation reserve (as per balance sheet of previous accounting year)**	**	**	**	14,518.23
14	**Earning per share (Face value Rs. 2/- each)** *(refer note 7)*				
	Basic (Rs.)				

Notes

1. The Company's operation predominantly comprise of only one segment - income from lease of medical equipments to Artemis Medicare Services Ltd. and therefore the figures shown above relate to that segment.

2.The Company (AGLSL), Aretmis Health Science Ltd. (AHSL), Artemis Medicare Services Ltd. (AMSL) and Athena Eduspark Ltd. (AEL), in their respective meeting held on 9th May, 2018, approved the draft Composite Scheme of Amalgamation between the AGLSL, AHSL AMSL and AEL and their respective shareholders & creditors, the same has also been filed with Bombay stock Exchange (BSE) and National Stock exchange (NSE) for their approval. The BSE and NSE vide their letters dated

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN : U85191DL2241PLC216530

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30,2019

(₹ in Lakh)

S No.	Particulars	Artemis Global Life Sciences Ltd			
		Quarter ended			Year ended
		30-Jun-19	31-Mar-19	30-Jun-18	31-Mar-19
		(Unaudited)	(Audited) (Refer note 6)	(Unaudited)	(Audited)
1	Revenue from operations	13,570.76	14,015.70	12,643.07	54,651.59
2	Other income	59.01	131.27	116.86	400.21
3	Total Income	13,629.77	14,146.97	12,759.93	55,051.80

Notes:-

1. The above results for the quarter ended 30th June, 2019 were reviewed by the Audit Committee meeting held on August 13th, 2019 and approved by the Board of Directors meeting held on August 14th, 2019. The Statutory Auditors have expressed an unmodified opinion on the aforesaid results.

2. The Group has adopted Ind AS 116 "Leases" effective 1 April 2019, as notified by the Ministry of Corporate Affairs (MCA) in the Companies(Indian Accounting Standard) Amendment Rules, 2019, retrospectively.with the cumulative effect of initially applying the standard recognised at the date of Initial application, with right to use asset being recognized at an amount equal to the lease liability, adjusted by the prepaid lease rent. This has resulted in the net impact of increase in the statement of Profit and Loss by Rs. 24.28 Lakh and Rs. 35.01 Lakh in the Depreciation and Finance cost respectively and a decrease in lease rent cost of Rs. 33.85 Lakh for the quarter ended 30th June, 2019.

3. Segment Reporting

Business segment

The company's operation predominantly comprise of only one business segment- Income from Healthcare services.

Geographical information

Geographical information analyses the company's revenue by the company's country of domicile (i.e. India)

Region	Quarter ended			Year ended
	30-Jun-19	31-Mar-19	30-Jun-18	31-Mar-19
India	9,039.93	8,912.20	7,760.80	33,342.28
Outside India	4,530.83	5,103.50	4,882.27	21,309.31
Total	13,570.76	14,015.70	12,643.07	54,651.59

4.The Company (AGLSL), Aretmis Health Science Ltd. (AHSL), Artemis Medicare Services Ltd. (AMSL) and Athena Eduspark Ltd. (AEL), in their respective meeting held on 9th May, 2018, approved the draft Composite Scheme of Amalgamation between the AGLSL, AHSL AMSL and AEL and their respective shareholders & creditors, the same has also been filed with Bombay stock Exchange (BSE) and National Stock exchange (NSE) for their approval. The BSE and NSE vide their letters dated 5th September 2018 & 14th September, 2018 respectively had communicated to the company that they have no adverse observation on the Composite Scheme of Amalgamation.

Subsequently, to the stock exchange approval the Composite Scheme of Amalgamation was filed with the National Company Law Tribunal New Delhi Bench -III, at New Delhi (NCLT).NCLT reserved the order for pronouncement, subject to clarification on August 1, 2019.

5. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under section 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.

6.The figures for the quarter ended March 31, 2019 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2019 and the unaudited published year to date figures up to December 31, 2018 being the date of the end of third quarter of the previous financial year, which were subject to limited review.

7. Previous period figures have been regrouped / reclassified wherever necessary to correspond with the current period classification / disclosures.

For and on behalf of the Board of Directors of

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

ANAND DUA & ASSOCIATES * NEW DELHI * CHARTERED ACCOUNTANTS

ONKAR S KANWAR
CHAIRMAN

PLACE: NEW DELHI
DATE: AUGUST 14, 2019

ARTEMIS GLOBAL LIFE SCIENCES LIMITED

(Formerly - PTL PROJECTS LIMITED)

Regd Office : 414/1, 4th Floor, DDA Commercial Complex, District Centre, Janakpuri, New Delhi - 110058

CIN : U85191DL2011PLC216530

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS
FOR THE QUARTER ENDED JUNE 30 ,2019